{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreiftgqrwesajz3ypnh4dg3pvq427s33mqjqdu5lws76lizem5dlhya",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3midfs3g3k432"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreibqcmshqtgerbz73lewghgvr5fvyctkgel5fsgx5xpa6d5l6pimfy"
    },
    "mimeType": "image/jpeg",
    "size": 851691
  },
  "path": "/news/2026-03-drug-results-uncontrolled-blood-pressure.html",
  "publishedAt": "2026-03-31T01:00:01.000Z",
  "site": "https://medicalxpress.com",
  "textContent": "The investigational drug tonlamarsen—which is designed to lower blood pressure by reducing the production of angiotensinogen, a protein that turns into the hormone that regulates blood pressure—caused a significant and sustained drop in angiotensinogen but its impact on blood pressure was less clear, according to a study presented at the American College of Cardiology's Annual Scientific Session (ACC.26).",
  "title": "Investigational drug delivers mixed results for uncontrolled blood pressure"
}